Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 10/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.59 |
| ▸ | CCR1 | P32246 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1147222 | 0.91 | FAAH (0.64) | FAAHEPHX2CCR1MAPTMEN1 | |
| SCHEMBL1147198 | 0.90 | FAAH (0.51) | FAAHEPHX2CCR1MAPTMEN1 | |
| SCHEMBL1147240 | 0.89 | FAAH (0.51) | FAAHEPHX2MAPTMEN1KMT2A | |
| SCHEMBL1147263 | 0.89 | EPHX2 (0.53) | FAAHEPHX2MAPTMEN1HTT | |
| Hydrochloric Acid SCHEMBL1147225 | 0.88 | FAAH (0.50) | FAAHEPHX2MAPTMEN1KMT2A | |
| SCHEMBL1146829 | 0.87 | EPHX2 (0.51) | FAAHEPHX2CCR1MAPT | |
| SCHEMBL1147145 | 0.85 | FAAH (0.48) | FAAHEPHX2MAPTMEN1KMT2A | |
| SCHEMBL1147272 | 0.85 | LIPE (0.58) | FAAHEPHX2MAPT | |
| SCHEMBL1147296 | 0.85 | FAAH (0.48) | FAAHEPHX2MAPTMEN1HTT | |
| SCHEMBL1147275 | 0.85 | EPHX2 (0.49) | FAAHEPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | claimed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-02-03 | — | — | US | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011012602-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028515-A1 | NEW PIPERIDINE DERIVATIVES | ADRA1D, ADORA1, H1-0 | FAAH 2059/4885EPHX2 3415/4885CCR1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.